NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
Valens Semiconductor Q3 2025 Financial Results and Business Update FAQ
TL;DR
Valens Semiconductor's sixth consecutive revenue growth and strong cash position provide competitive investors with a resilient company poised for strategic acquisitions and market expansion.
Valens Semiconductor achieved 3Q25 revenue of $17.3M exceeding guidance, with 63.0% GAAP gross margin and $(4.3)M adjusted EBITDA loss, while maintaining $93.5M cash with zero debt.
Valens Semiconductor's medical advancements including 4K colonoscopes and machine vision systems improve healthcare diagnostics and industrial automation, creating safer and more efficient technologies for society.
Valens Semiconductor launched the market's first end-to-end MIPI A-PHY platform and three VA7000-based medical products including a groundbreaking single-use 4K colonoscope for enhanced medical imaging.
Found this article helpful?
Share it with your network and spread the knowledge!
Valens reported Q3 2025 revenue of $17.3M, significantly above guidance of $15.1–$15.6M, marking the sixth consecutive quarter of growth. GAAP gross margin was 63.0% and adjusted EBITDA loss was $(4.3)M, better than the expected $(7.4)–$(6.8)M range.
The Cross-Industry Business generated $13.2M in revenue (~75% of total), up from $12.8M in Q2 2025 and $9.4M in Q3 2024, with gross margin improving to 69.1% due to product mix and strong VS3000 chipset adoption in ProAV.
Automotive revenue decreased to $4.1M from $4.3M in Q2 2025 and $6.6M in Q3 2024 primarily due to continued weakness in the automotive market from tariff impacts, though gradual improvement is expected over coming quarters.
Valens is expanding into industrial machine vision with the VA7000 chipset for factory automation and advancing in medical markets with three VA7000-based endoscopy products, including a first single-use 4K colonoscope, though meaningful revenue from medical is expected to take several quarters due to qualification timelines.
The company ended Q3 with $93.5M in cash, cash equivalents, and short-term deposits, maintains zero debt, and spent $3.6M on share repurchases, demonstrating strong financial resilience and readiness for growth opportunities.
For Q4 2025, Valens expects revenue between $18.2M-$18.9M, adjusted EBITDA loss between $(4.6)M-$(4.2)M, and gross margins of 58.0%-60.0%. Full year 2025 revenue guidance of $69.4M-$70.1M represents approximately 20% year-over-year growth at the midpoint.
The company faces mixed visibility into year-end with tariff impacts posing headwinds, particularly in automotive, and automotive gross margins decreased to 43.2% due to product version mix and manufacturing line transition expenses.
Stonegate expects steady growth through 2026 as ProAV normalizes and machine vision and medical programs ramp, with automotive stabilizing alongside ongoing A-PHY ecosystem progress.
Curated from Reportable
